Tirzepatide Medical Weight Loss in Fort Mill, SC
A Dual-Action Weight Loss Medication
Tirzepatide is a once-weekly injectable that activates two gut hormone receptors, GIP and GLP-1, rather than one. It reduces appetite, slows how quickly the stomach empties and helps regulate blood sugar, which together make it easier to eat less without fighting constant hunger.
In SURMOUNT-1, a 72-week trial of 2,539 adults funded by the manufacturer, average weight loss was 15.0% at the 5 mg dose, 19.5% at 10 mg and 20.9% at 15 mg, compared with 3.1% on placebo. Between 85% and 91% of participants lost at least 5% of their body weight, depending on dose.
At Carolina Trim Clinic in Fort Mill, tirzepatide is prescribed and monitored in person. Your dose, your tolerance and your progress are reviewed at the office rather than moved along by an automatic schedule.


Supervised Dosing, Measured Progress
Tirzepatide is approved for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition, used alongside a reduced-calorie diet and increased physical activity. It is a prescription medication, and it is worth being careful where yours comes from.
Side effects are most often gastrointestinal, such as nausea, and are usually mild to moderate and concentrated during the first weeks as the dose steps up. The approved label carries a boxed warning about thyroid C-cell tumors observed in rats, and states the medication is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Because rapid weight loss takes muscle as well as fat, we track circumference and body shape on our Styku 3D scanner and talk about protein and resistance training from the beginning rather than after the fact.
Tirzepatide acts on two hormone pathways instead of one, which is why average results in trials have been higher than with single-pathway GLP-1 medications.

Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on both the GIP and GLP-1 receptors. Average weight loss has been higher in the tirzepatide trials, though the two medications were studied separately rather than head to head in every population. Which one suits you is decided at your consultation, based on your history and how you respond.
In SURMOUNT-1, a 72-week trial of 2,539 adults, average weight loss was 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg, compared with 3.1% on placebo. Individual results vary, and the trial paired the medication with a reduced-calorie diet and increased physical activity.
The approved label states it is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and it is not for use during pregnancy. Tell us at your consultation about any history of pancreatitis, gallbladder disease, thyroid disease or diabetes medications.
Appetite generally returns once the medication stops, and the withdrawal trials show most people regain a large share of the weight within a year. We treat maintenance as a phase of the program rather than the end of it. Call 803-548-8746 to talk through what that looks like.
.png)